[Effect of pidotimod on the function of the human immune system: in vitro and ex vivo study].
Borghi
M O
MO
Istituto di Medicina Interna, Malattie Infettive e Immunopatologia, Università di Milano, Italia.
Minonzio
F
F
Fain
C
C
Carbonelli
V
V
Barcellini
W
W
Del Papa
N
N
La Rosa
L
L
Piona
A
A
Gambini
D
D
Meroni
P L
PL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000378:metabolism; D007375:Interleukin-1 / Q000096:biosynthesis / Q000378:metabolism; D007376:Interleukin-2 / Q000096:biosynthesis / Q000235:genetics; D015850:Interleukin-6 / Q000096:biosynthesis / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008934:Mitogens / Q000494:pharmacology; D016853:Muromonab-CD3 / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects; D010835:Phytohemagglutinins / Q000494:pharmacology; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*; D053778:Thiazolidines
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D008934:Mitogens; D016853:Muromonab-CD3; D010835:Phytohemagglutinins; D013844:Thiazoles; D053778:Thiazolidines; C064893:pidotimod; D007371:Interferon-gamma; D013755:Tetradecanoylphorbol Acetate; D011761:Pyrrolidonecarboxylic Acid